Kornimate/medical-research-clean huggingface dataset:
international research consortium on dengue risk assessment, management, and surveillance

Conditions: Dengue Fever

Summary: improvements in diagnosis of dengue fever and prediction of which patients will get more severe disease are urgently needed to improve the treatment of patients with dengue. this is very important in places with many people who suffer from dengue but have limited health care resources. this study will enroll patients with fever which may be caused by dengue in 6 countries with high incidence of dengue over two continents (brazil, cambodia, el salvador, indonesia, malaysia and vietnam). all patients will be followed by a doctor with blood tests and exams until they recover. symptoms and laboratory tests will be followed so that the cause of fever can be determined. for patients who have dengue, the investigators will look for symptoms and tests which indicate more serious disease. this study will help to determine how to identify patients with dengue fever based on symptoms and simple laboratory tests and those who will get more serious disease. it will also help to define a more standardized management of patients with dengue fever.

improvements in clinical diagnosis of dengue and risk prediction for severe disease are urgently needed to improve overall clinical care, especially in settings with a high case burden where appropriate allocation of limited resources is crucial to outcome. in this work package 10,000 outpatients with undifferentiated fever, consistent with possible dengue, will be recruited within 3 days of fever onset in 6 endemic countries (brazil, cambodia, el salvador, indonesia, malaysia and vietnam), and will be followed daily until full recovery. clinical features and simple laboratory parameters differentiating dengue from other febrile illness will be identified, and, among those with confirmed dengue, risk factors for progression to more severe disease will be evaluated. as well as contributing to the development of diagnostic and prognostic algorithms the clinical cohort has considerable potential towards standardisation of procedures for dengue management and reporting.

Eligibility criteria:
inclusion criteria: * \>= 5 years of age * fever for less than 72 hours exclusion criteria: * presence of localizing signs suggestive of another diagnosis * not likely to come back for daily follow-up * complications or signs of severe disease

Keywords: dengue warning signs latin america south east asia other febrile illnesses dengue classification
assessing repetitive transcranial magnetic stimulation as a treatment for refractory depression (rtms)

Conditions: Depression

Summary: the hypothesis of this study was that transcranial magnetic stimulation (tms) focused on hyperfunctional cerebral areas should be more effective in treating depressive symptoms than stimulations not taking into account the functional specificity of the patient. the goal was to compare the effects of "guided" tms, using neuroimaging to guide tms on dysfunctional cortical regions individually detected by neuroimaging, with "standard tms", as used in most studies, over the left prefrontal cortex, and with sham tms, in patients with resistant depression.

the objectives of the study were : * to localize the site of lowest frontal activity in each patient with resistant depression, using pet to measure regional cerebral metabolic rates for glucose (rcmrglu). * to demonstrate that high-frequency tms (10hz) guided on that site is more effective than standard or sham tms, in resistant depressed patients, using a doubled blind controlled procedure. * to assess the effects of tms on regional cerebral metabolism using rcmrglu pet after 10 sessions of tms treatments. depressed patients meeting dsm-iv criteria for major depressive disorder, aged between 18 and 55, have been included. they met criteria for depression resistant to antidepressant drugs they were randomised in 3 groups: guided prefrontal tms, standard left prefrontal and sham left prefrontal tms. rtms was administered daily on working days, for two weeks. ten stimuli per second (10hz) were applied in 20 courses so that patients received 1600 stimuli per day. guided tms was on a prefrontal target corresponding to the highest statistically significant hyperfunctional cluster determined with rcmrglu pet. standard stimulation was left pre-frontal, 5 cm anterior to the optimal stimulation point of the abductor pollices brevis. stimulation strength was chosen at 90% relative to motor threshold. sham rtms used a procedure identical to the real standard treatment, but using a sham coil.

Eligibility criteria:
inclusion criteria: * major depression (according to dsm-iv)resistant to at least two medical antidepressant treatment of different pharmacological action, prescribed for at least one month each at an effective dosage, without therapeutical result. * hospitalisation in the service of an investigator * informed consent signed exclusion criteria: * presence of metallic parts inside the body (pace-maker, vascular clip, cardiac valve, prothesis...) * severe somatic or central nervous system disease * familial history of comitiality * pregnancy

Keywords: resistant depression transcranial magnetic stimulation, neuroimaging
effects of intermittent hypoxia-hyperoxia in older adults

Conditions: Sedentary Behavior; Frailty; Older Adults

Summary: the supply of oxygen is essential for energy production, recovery from efforts, and human life. intermittent hypoxia-hyperoxia exposure (ihhe) is a novel technique in which the subject is exposed to a respiratory environment with reduced oxygen fraction, controlled through a specific software, using a facial mask and a hypoxic generation device. the objective of this study is to determine if there is a relationship between intermittent hypoxia-hyperoxia exposure and cardiorespiratory condition, blood pressure, and arterial oxygen saturation. according to our hypothesis, acute ihhe in elderly adults may influence cardiorespiratory condition, inflammatory biomarkers, blood pressure, and arterial oxygen saturation. the study will be conducted as a randomized clinical trial. the subjects will be divided into two groups: the experimental group will undergo an ihhe session, breathing air with an oxygen concentration (fio2) ranging from 10-14% for 1-5 minutes, with 1-3 minutes of rest in hyperoxia (fio2 30-40%) for a total of 4-8 cycles, based on their acute response to hypoxia. the sham group will undergo a 5-cycle protocol with an fio2 of 21%. both groups will follow a 6-week protocol with three weekly sessions (monday, wednesday, and friday).


Eligibility criteria:
inclusion criteria: * being over 65 years old. * having no previous experience in hypoxic training. * engaging in less than 150 minutes of physical activity per week. exclusion criteria: * having any pathology that prevents the subject from being independent in terms of walking and functionality. * subjects with impaired cognitive abilities. * subjects with pulmonary hypertension, decompensated heart or respiratory disease. * to have or have had cancer

Keywords: hypoxic training elderly heart rate variability
activin a and inhibin a in predicting outcome of pregnancies of unknown location after assisted reproductive technology

Conditions: Ectopic Pregnancies

Summary: the purpose of this study is to determine the predictive value of a single serum determination of activin a and inhibin a for the prognosis of ectopic pregnancy after in vitro fertilization (ivf) cycles, in both native and donated oocytes.

ectopic pregnancy (ep) is one of the most common pathologies seen in emergency gynaecology practice. early diagnostic of this situation is a clinical objective because it remains an important cause of maternal morbidity and mortality worldwide. currently, transvaginal ultrasound scan (tvs) allow ascertain the location of the pregnancy. however, the diagnosis of ep is complicated by a nonspecific clinical presentation and the inconclusive results in some cases of transvaginal ultrasound at first presentation. for this reason several biomarkers have been investigated to accurately detect the establishment of pregnancy and predict its outcome as early as possible. these biomarkers include: markers of abnormal embryo/trophoblast growth (β-subunit of hcg, activin a, etc), markers of abnormal corpus luteum function (progesterone, inhibin a, etc), markers of a growing pregnancy in the fallopian tube (creatine kinase, vascular endothelial growth factor, etc), markers of inflammation and peritoneal irritation (cancer antigen 125, interleukin-6, etc), and uterine markers of normal implantation (leukaemia inhibitory factor and glycodelin). β-hcg and progesterone are usually used in clinical practice and activin a and inhibin a have recently shown promising results.

Eligibility criteria:
inclusion criteria: * patients with pregnancy of unknown location (pul) diagnosed 22 - 27 days after oocyte retrieval, at first ultrasound routine control (a "pregnancy of unknown location" (pul) is a term used to classify a women with a positive pregnancy test and an empty uterus with no signs of an intrauterine or extrauterine pregnancy on a transvaginal ultrasound scan.) * patients with intrauterine pregnancy : viable intrauterine pregnancy (iup) an intrauterine gestational sac containing a fetal pole with visible cardiac activity * patients with ectopic pregnancy (tubal ectopic pregnancy): an empty endometrial cavity with: (i) an inhomogeneous adnexal mass or (ii) an empty extrauterine gestational sac seen as hyperechoic ring or (iii) an extrauterine gestational sac with a yolk sac and/or fetal pole with or without cardiac activity
effects of carboplatin and gemcitabine on stage iiib pleural effusion and stage iv lung cancer

Conditions: Stage IV Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer

Summary: the purpose of this study is to find better treatment for lung cancer and to find out what effects the combined treatment of carboplatin and gemcitabine when given with or without dexamethasone have on cancer. this study will determine if dexamethasone, when given before standard chemotherapy will increase the cancer fighting effects and reduce the side effects of chemotherapy.

subjects enrolled in the study will be placed in one of two treatment arms. all subjects have a 50-50 chance of being placed into either treatment arm. treatment arm 1 will receive chemotherapy alone, treatment arm 2 will receive chemotherapy with dexamethasone given pre-treatment.

Eligibility criteria:
inclusion criteria: * untreated, stage iiib with pleural effusion * untreated, stage iv, non-small cell lung cancer * recurrent after surgery if no previous radiation therapy or chemotherapy were administered as part of their primary treatment, except for palliative radiotherapy * 18 years of age or older * ecog ps 0, 1 or 2 * at least one target lesion according to the recist criteria * adequate organ and marrow function exclusion criteria: * previous cancer history unless they have had curative treatment completed at least 5 years prior to entry. * no previous radiotherapy, chemotherapy or immunotherapy for nsclc, except for radiation therapy to the brain to control metastasis, bone to control pain, or lung to relieve bronchial obstruction. * no radiation therapy for any previous cancer to more than 25% of bone marrow. * uncontrolled, intercurrent illness * non-study corticosteroids * pregnant women * peripheral neuropathy greater than grade 1 * uncontrolled seizures, central nervous system disorders * major surgery within 4 weeks of the start of study treatment * lack of complete recovery from major surgery. * glaucoma * lack of physical integrity of upper gastrointestinal tract, inability to swallow tablets * severe acquired or hereditary immunodeficiency * patients with brain metastases must receive definitive treatment (radiation, surgery or both) and be clinically and radiologically stable for 4 weeks \& off corticosteroids for at least 2 weeks prior to randomization.

Keywords: untreated lung cancer non-small cell gemcitabine gemzar carboplatin dexamethasone
comparative effect of two educational videos for people with knee osteoarthritis (video)

Conditions: Knee Osteoarthritis; Patient Empowerment

Summary: education is an important part of knee osteoarthritis management. the aim of education is to help people with knee osteoarthritis make the best choices for them in terms of their treatment and lifestyle behaviours. traditional education that describes the condition simplistically in terms of the joint damage and describes the cause of osteoarthritis solely with respect to loading through the joint can lead to activity avoidance and pessimism about the future progression of symptoms. an alternative is to provide the information about knee osteoarthritis management with the aim of giving hope for the future and building motivation and confidence to be physically active. this study will compare two educational videos that cover the same topics but with a contrasting 'discourse'. the experimental video has an 'empowerment and participatory' discourse, while the comparator or control video has a typical 'disease and impairment' discourse. the experimental video minimises mention of joint damage and instead corrects misconceptions about knee osteoarthritis, addresses common barriers to physical activity and incorporates behaviour change techniques such as social learning and modelling of desired behaviours. in this randomised controlled trial, people who report a history of knee problems consistent with knee osteoarthritis will complete questionnaires to determine their self-efficacy for managing knee osteoarthritis pain and their fear of movement. the participants will also be asked about their expectations for the future, their level of motivation to be physically active, and their knowledge about knee osteoarthritis. participants will then be allocated one of the videos and asked to watch it before repeating the questionnaires.


Eligibility criteria:
inclusion criteria: * live in australia; * are aged 45 years or over; * have experienced activity-related knee pain during the past 3 months or have been told by a health professional that they have knee oa, ; and * are able to easily understand verbal and written english language. exclusion criteria: * have had a hip or knee joint replacement; * are scheduled/referred to see an orthopaedic surgeon or are already on a waiting list for hip or knee joint replacement; * have any type of systemic arthritis (e.g. rheumatoid arthritis, gout), or have morning stiffness that lasts longer than 30 minutes; * have a health condition that makes them unable to walk (since it will be difficult for people who cannot walk to follow the recommendations made in either video); * have seen a health professional for their knee pain during the previous six months

Keywords: knee osteoarthritis patient education health information empowerment discourse video randomised controlled trial
exploration of feasability of blood and saliva proteomic analysis through harvesting by silica matrix (nanodx-cov-19)

Conditions: Covid19

Summary: phase 1: 25 patients with a pcr-based diagnosis of covid-19 will be be included to give 500 microliters of saliva and a 3 ml sample of blood for proteomic analysis; a drop of blood will also be put in a device connected to a silica matrix to perform spectrometric analyses. 25 patients with a non-covid-19 respiratory infection will be included for the same samples. the proteomic analyses will be performed from classicaly draught blood, blood drop on silica, and saliva, to search for discriminating profiles between covid-19 and non-covid-19. phase 2: 150 patients with a suspected covid-19 will be included at the same time than the covid-19pcr is performed ; they will have a sample of saliva and of a drop of blood for proteomic analysis, whose results will be matched with pcr results.

phase 1: derivation analyses 25 patients with a pcr-based diagnosis of covid-19 will be be included to give 500 microliters of saliva and a 3 ml sample of blood for proteomic analysis; a drop of blood will also be put in a device connected to a silica matrix to perform spectrometric analyses. 25 patients with a non-covid-19 respiratory infection will be included for the same samples. the proteomic analyses will be performed from classicaly draught blood, blood drop on silica, and saliva, to search for discriminating profiles between covid-19 and non-covid-19. phase 2: confirmation analyses 150 patients with a suspected covid-19 will be included at the same time than the covid-19pcr is performed ; they will have a sample of saliva and of a drop of blood for proteomic analysis, whose results will be matched with pcr results.

Eligibility criteria:
phase 1: inclusion criteria for group 1: * positive covid-19 pcr * clinical signs evocative of covid-19 exclusion criteria for group 1: * asymptomatic covid-19 infection inclusion criteria for group 1: * negative covid-19 pcr * acute respiratory infection exclusion criteria for group 1: * none phase 2 inclusion criteria: * suspicion of covid-19 * sample for covid-19 pcr planned or performed the same day * admission ot emergency room exclusion criteria: * past known covid-19
scapular stabilization vs functional exercises on chronic neck pain

Conditions: Neck Pain

Summary: this project is a randomized clinical trial, will be conducted to check the comparative effects of scapular stabilization versus scapular functional exercises in patients with chronic neck pain. study duration will be of 8 months, convenient sampling will be done, subject following eligibility criteria from amina physical therapy and rehab centre lahore, will be randomly allocated in two groups, baseline assessment will be done, group a participants will be given baseline treatment along with scapular stabilization exercises, group b participants will be given baseline treatment along with scapular functional exercises. assessment will be done in 4th week and 8th week via, visual analogue scale for neck pain, function of neck will be assessed by neck disability index and inclinometer measurements of cervical ranges,3 sessions per week will be given, data will be analyzed by using spss version 21.

in recent years musculoskeletal related problems are the leading cause of discomfort in people worldwide. chronic neck pain is among the most commonly reported problems to physicians. even before reporting to clinics there is long history of using over the counter pain killers. for the duration of rehabilitation in patients who are suffering from chronic neck pain, exercising has been considered one of the maximum proof-based modalities. rehabilitation exercises that aim to return functionality of the scapular muscles are deemed necessary to render a successful result on chronic neck pain. in previous researches no one explains the specific treatment protocol in scapular exercises. the current study has compared the effects of scapular stabilization exercises and scapular functional exercises protocol and also compare which is more effective for chronic neck pain.

Eligibility criteria:
inclusion criteria: * patients of both genders.(18-35 years of age) * patients having chronic neck pain(\>3 months duration) * patient with restricted rom of cervical. * vas≥4(16) * ndi ≥10 exclusion criteria: * history of head, neck, cervical spine and shoulder injury. * history of cervical radiculopathy * history of malignancy, scoliosis, torticollis * diagnosed cases of disc prolapse, stenosis, herniation, spondylolisthesis, osteoporosis, and those with current use of any medication or physical therapy treatment were excluded.

Keywords: neck pain scapular exercises range of motion disability
pharmacokinetic trial of decitabine (dacogen) administered as a 3-hour infusion to patients with acute myelogenous leukemia or myelodysplastic syndrome

Conditions: Leukemia

Summary: the purpose of this study is to determine the pharmacokinetics (pk) of decitabine administered to patients with myelodysplastic syndrome (mds) or acute myeloid leukemia (aml).


Eligibility criteria:
inclusion criteria: each patient had to meet the following criteria to be eligible for the study: 1. patients with mds (de novo or secondary) must have been 60 years or older and have had disease fitting any of the recognized french-american-british classifications or chronic myelomonocytic leukemia (with white blood cell \[wbc\] \<12,000/μl) and have had an international prognostic scoring system score of ≥1.5 as determined by complete blood count, bone marrow assessment and bone marrow cytogenetics within 30 days of study entry. 2. patients with aml (≥30% bone marrow blasts) must have been age 18 years or older and had previously received standard induction chemotherapy and/or had failed approved therapies. 3. must have had eastern cooperative oncology group (ecog) performance status of 0 to 2. 4. must have signed an institutional review board (irb)-approved informed consent form, indicating his/her awareness of the investigational nature of this study and its potential hazards prior to initiation of any study-specific procedures or treatment. 5. must have had adequate renal and hepatic function (creatinine ≤2.0 mg/dl, total bilirubin \<2.0 mg/dl, aspartate aminotransferase (ast) and alanine aminotransferase (alt) \<3.0 x institutional upper limit of normal). 6. must have had life expectancy of at least 12 weeks. 7. must have recovered from all toxic effects of all prior therapy before entry into this study. exclusion criteria: 1. patients with mds must not have been candidates for high-dose chemotherapy, bone marrow or stem cell transplant. 2. must not have had acute promyelocytic leukemia (m3 classification). 3. must not have received immunosuppressive therapy for 30 days prior to study entry. 4. must not have had central nervous system (cns) leukemia. 5. must not have received systemic corticosteroids, interferon, interleukins or other hormonal therapy within 30 days prior to study entry. use of corticosteroids (topical and inhaled corticosteroids) was permitted and prophylactic steroids may have been used to treat or prevent transfusion reactions.

Keywords: acute myelogenous leukemia myelodysplastic syndrome cancer
national registry for egyptian pediatric neuromuscular diseases

Conditions: Spinal Muscular Atrophy; Muscular Dystrophy; Muscle Diseases; Myasthenic Syndromes; Polyneuropathies

Summary: our aim is to establish multi-center national egyptian database of information for inherited and acquired neuromuscular diseases in infants and children from 0 to 18 years of age.

aims: an open-ended multi-center, national egyptian study to collect and analyze data for children with neuromuscular diseases (nmd) inherited nmd (spinal muscular atrophy (sma), duchenne/becker and congenital muscular dystrophies (dmd/bmd, cmd), congenital myopathies, and congenital myasthenic syndromes) and acquired nmd (neuropathies, myasthenia gravis and myositis). participants: eligible infants and children with inherited and acquired neuromuscular diseases. design: this study is a prospective cohort study. outcome measures: motor development assessment, respiratory and cardiac examination.

Eligibility criteria:
inclusion criteria: * weakness, hypotonia. * nerve conduction study and electromyographic confirmation of lower motor neuron affection. exclusion criteria: * chromosomal diseases. * malformations and deformations.

Keywords: spinal muscular atrophy muscular dystrophy muscle diseases myasthenic syndromes polyneuropathies myopathies